These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30657422)

  • 1. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
    Cazzola M; Page C; Calzetta L; Matera MG
    Pharm Pat Anal; 2018 Nov; 7(6):249-257. PubMed ID: 30657422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.
    Cazzola M; Calzetta L; Rogliani P; Matera MG
    Expert Opin Investig Drugs; 2019 Oct; 28(10):827-833. PubMed ID: 31474120
    [No Abstract]   [Full Text] [Related]  

  • 4. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
    Singh D; Martinez FJ; Watz H; Bengtsson T; Maurer BT
    Respir Res; 2020 Feb; 21(1):47. PubMed ID: 32041601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ensifentrine: First Approval.
    Keam SJ
    Drugs; 2024 Sep; 84(9):1157-1163. PubMed ID: 39196510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials.
    Cazzola M; Page C; Calzetta L; Singh D; Rogliani P; Matera MG
    Immunotherapy; 2023 Dec; 15(18):1511-1519. PubMed ID: 37779474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.
    Bjermer L; Abbott-Banner K; Newman K
    Pulm Pharmacol Ther; 2019 Oct; 58():101814. PubMed ID: 31202957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective.
    Gan Q; Wu Y; Su X; Wang J; Zhang H; Zhang N; Wu K
    Am J Respir Crit Care Med; 2024 Jan; 209(2):223-224. PubMed ID: 37939381
    [No Abstract]   [Full Text] [Related]  

  • 9. Dual PDE 3/4 inhibition: a novel approach to airway disease?
    Wedzicha JA
    Lancet Respir Med; 2013 Nov; 1(9):669-70. PubMed ID: 24429260
    [No Abstract]   [Full Text] [Related]  

  • 10. Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
    Donohue JF; Rheault T; MacDonald-Berko M; Bengtsson T; Rickard K
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1611-1622. PubMed ID: 37533771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.
    Calzetta L; Cazzola M; Page CP; Rogliani P; Facciolo F; Matera MG
    Pulm Pharmacol Ther; 2015 Jun; 32():15-23. PubMed ID: 25899618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
    Singh D; Lea S; Mathioudakis AG
    Drugs; 2021 Nov; 81(16):1821-1830. PubMed ID: 34731461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia.
    Turner MJ; Matthes E; Billet A; Ferguson AJ; Thomas DY; Randell SH; Ostrowski LE; Abbott-Banner K; Hanrahan JW
    Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(1):L59-70. PubMed ID: 26545902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research prospect of cyclic nucleotide phosphodiesterase 3/4 inhibitors in chronic obstructive pulmonary disease].
    Wang ZH; Wu F; Deng ZS; Dai CQ; Cai GN; Zhou YM
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Sep; 47(9):876-884. PubMed ID: 39266490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4.
    Turner MJ; Dauletbaev N; Lands LC; Hanrahan JW
    J Pharmacol Exp Ther; 2020 Dec; 375(3):414-429. PubMed ID: 33012706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
    Martin C; Burgel PR; Roche N
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2363-2373. PubMed ID: 34429594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials.
    Mahler DA; Bhatt SP; Rheault T; Reyner D; Bengtsson T; Dixon A; Rickard K; Singh D
    Expert Rev Respir Med; 2024 Aug; 18(8):645-654. PubMed ID: 39106052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
    Abbott-Banner KH; Page CP
    Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone.
    Calzetta L; Page CP; Spina D; Cazzola M; Rogliani P; Facciolo F; Matera MG
    J Pharmacol Exp Ther; 2013 Sep; 346(3):414-23. PubMed ID: 23766543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE inhibitors currently in early clinical trials for the treatment of asthma.
    Matera MG; Page C; Cazzola M
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1267-75. PubMed ID: 24865624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.